Comparative Cost-Effectiveness Analysis of Multiple First-Line Treatments for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer in Japan. - Morimoto K; Moriwaki K; Nishikawa Y; Maeda T; Toyama M; Agatsuma N; Kojima S; Utsumi T; Takahashi Y; Shimozuma K; Nakayama T (PharmacoEconomics - open, 2026)